auranofin

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Stem definition	Drug id	CAS RN
	4122	34031-32-8

Stem definition

Drug id

CAS RN

4122

34031-32-8

Description:

Molecule	Description
Synonyms: auranofin ridaura	An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious. Molecular weight: 678.48 Formula: C20H34AuO9PS CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

auranofin
ridaura

An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious.

Molecular weight: 678.48
Formula: C20H34AuO9PS
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Dose	Unit	Route
6	mg	O

Dose

Unit

Route

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	60 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	20 %

Property

Value

Reference

BDDCS (Biopharmaceutical Drug Disposition Classification System)

Benet LZ, Broccatelli F, Oprea TI

EoM (Fraction excreted unchanged in urine)

60 %

Benet LZ, Broccatelli F, Oprea TI

BA (Bioavailability)

20 %

Date	Agency	Company	Orphan
May 24, 1985	FDA	PROMETHEUS LABS

Date

Agency

Company

Orphan

May 24, 1985

FDA

PROMETHEUS LABS

Pharmacologic Action:

Source	Code	Description
ATC	M01CB03	MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS SPECIFIC ANTIRHEUMATIC AGENTS Gold preparations
CHEBI has role	CHEBI:33231	antitubercular agent
CHEBI has role	CHEBI:35480	analgesic
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:35705	immunosuppressive agent
CHEBI has role	CHEBI:35842	antirheumatic drug
CHEBI has role	CHEBI:64670	EC 1.8.1.9 (thioredoxin reductase) inhibitor
CHEBI has role	CHEBI:64946	anti-HIV agent
CHEBI has role	CHEBI:171664	antiamoebic agent
MeSH PA	D018501	Antirheumatic Agents

Source

Code

Description

ATC

M01CB03

MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
SPECIFIC ANTIRHEUMATIC AGENTS
Gold preparations

CHEBI has role

CHEBI:33231

antitubercular agent

CHEBI has role

CHEBI:35480

analgesic

CHEBI has role

CHEBI:35610

antineoplastic agent

CHEBI has role

CHEBI:35705

immunosuppressive agent

CHEBI has role

CHEBI:35842

antirheumatic drug

CHEBI has role

CHEBI:64670

EC 1.8.1.9 (thioredoxin reductase) inhibitor

CHEBI has role

CHEBI:64946

anti-HIV agent

CHEBI has role

CHEBI:171664

antiamoebic agent

MeSH PA

D018501

Antirheumatic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Rheumatoid arthritis	indication	69896004	DOID:7148
Psoriasis with arthropathy	off-label use	33339001
Felty's syndrome	off-label use	57160007	DOID:11042
Juvenile rheumatoid arthritis	off-label use	410795001
Necrotizing enterocolitis in fetus OR newborn	contraindication	2707005
Hypertensive disorder	contraindication	38341003	DOID:10763
Eczema	contraindication	43116000
Chronic heart failure	contraindication	48447003
Fibrosis of lung	contraindication	51615001	DOID:3770
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Colitis	contraindication	64226004	DOID:0060180
Diabetes mellitus	contraindication	73211009	DOID:9351
Sjögren's syndrome	contraindication	83901003	DOID:12894
Leukopenia	contraindication	84828003	DOID:615
Kidney disease	contraindication	90708001	DOID:557
Urticaria	contraindication	126485001
Inflammatory disease of liver	contraindication	128241005
Disease of blood AND/OR blood-forming organ	contraindication	191124002	DOID:74
Disease of liver	contraindication	235856003	DOID:409
Eruption of skin	contraindication	271807003	DOID:0050486
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Ultraviolet light therapy	contraindication	363695005
Erythroderma	contraindication	399992009
Severe Debilitation	contraindication

Disease

Relation

SNOMED_ID

DOID

Rheumatoid arthritis

indication

69896004

DOID:7148

Psoriasis with arthropathy

off-label use

33339001

Felty's syndrome

off-label use

57160007

DOID:11042

Juvenile rheumatoid arthritis

off-label use

410795001

Necrotizing enterocolitis in fetus OR newborn

contraindication

2707005

Hypertensive disorder

contraindication

38341003

DOID:10763

Eczema

contraindication

43116000

Chronic heart failure

contraindication

48447003

Fibrosis of lung

contraindication

51615001

DOID:3770

Systemic lupus erythematosus

contraindication

55464009

DOID:9074

Colitis

contraindication

64226004

DOID:0060180

Diabetes mellitus

contraindication

73211009

DOID:9351

Sjögren's syndrome

contraindication

83901003

DOID:12894

Leukopenia

contraindication

84828003

DOID:615

Kidney disease

contraindication

90708001

DOID:557

Urticaria

contraindication

126485001

Inflammatory disease of liver

contraindication

128241005

Disease of blood AND/OR blood-forming organ

contraindication

191124002

DOID:74

Disease of liver

contraindication

235856003

DOID:409

Eruption of skin

contraindication

271807003

DOID:0050486

Pregnancy, function

contraindication

289908002

Thrombocytopenic disorder

contraindication

302215000

DOID:1588

Neutropenic disorder

contraindication

303011007

DOID:1227

Ultraviolet light therapy

contraindication

363695005

Erythroderma

contraindication

399992009

Severe Debilitation

contraindication

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.48	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.44	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.65	DRUG MATRIX
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN		Ki	6.22	DRUG MATRIX
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	6.02	DRUG MATRIX
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	6.41	DRUG MATRIX
Arachidonate 5-lipoxygenase	Enzyme	P09917	LOX5_HUMAN				WOMBAT-PK
Thioredoxin reductase 1, cytoplasmic	Enzyme	Q16881	TRXR1_HUMAN				WOMBAT-PK
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.92	DRUG MATRIX
Transient receptor potential cation channel subfamily A member 1	Ion channel	O75762	TRPA1_HUMAN	ACTIVATOR	EC50	6	IUPHAR

Target

Class

Pharos

UniProt

Action

Type

Activity value
(-log[M])

Mechanism
action

Bioact source

MoA source

Alpha-2A adrenergic receptor

GPCR

P08913

ADA2A_HUMAN

6.48

DRUG MATRIX

Alpha-2B adrenergic receptor

GPCR

P18089

ADA2B_HUMAN

6.44

DRUG MATRIX

D(3) dopamine receptor

GPCR

P35462

DRD3_HUMAN

6.65

DRUG MATRIX

Glucocorticoid receptor

Nuclear hormone receptor

P04150

GCR_HUMAN

6.22

DRUG MATRIX

Adenosine receptor A3

GPCR

P0DMS8

AA3R_HUMAN

6.02

DRUG MATRIX

D(4) dopamine receptor

GPCR

P21917

DRD4_HUMAN

6.41

DRUG MATRIX

Arachidonate 5-lipoxygenase

Enzyme

P09917

LOX5_HUMAN

WOMBAT-PK

Thioredoxin reductase 1, cytoplasmic

Enzyme

Q16881

TRXR1_HUMAN

WOMBAT-PK

Tyrosine-protein kinase Fyn

Kinase

P06241

FYN_HUMAN

IC50

5.92

DRUG MATRIX

Transient receptor potential cation channel subfamily A member 1

Ion channel

O75762

TRPA1_HUMAN

ACTIVATOR

EC50

IUPHAR

External reference:

ID	Source
4018014	VUID
N0000146358	NUI
D00237	KEGG_DRUG
4018014	VANDF
C0004320	UMLSCUI
CHEBI:2922	CHEBI
CHEMBL1366	ChEMBL_ID
D001310	MESH_DESCRIPTOR_UI
DB00995	DRUGBANK_ID
6306	IUPHAR_LIGAND_ID
3972	INN_ID
3H04W2810V	UNII
16667669	PUBCHEM_CID
1227	RXNORM
1189	MMSL
234310	MMSL
4231	MMSL
d00818	MMSL
002398	NDDF
18002004	SNOMEDCT_US
387100001	SNOMEDCT_US
3H04W2810V	INXIGHT DRUGS

Source

4018014

VUID

N0000146358

NUI

D00237

KEGG_DRUG

4018014

VANDF

C0004320

UMLSCUI

CHEBI

ChEMBL_ID

MESH_DESCRIPTOR_UI

DRUGBANK_ID

IUPHAR_LIGAND_ID

INN_ID

UNII

PUBCHEM_CID

RXNORM

1189

MMSL

234310

MMSL

4231

MMSL

d00818

MMSL

002398

NDDF

18002004

SNOMEDCT_US

387100001

SNOMEDCT_US

3H04W2810V

INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
RIDAURA	HUMAN PRESCRIPTION DRUG LABEL	1	54766-093	CAPSULE	3 mg	ORAL	NDA	23 sections
RIDAURA	HUMAN PRESCRIPTION DRUG LABEL	1	54766-093	CAPSULE	3 mg	ORAL	NDA	23 sections
RIDAURA	HUMAN PRESCRIPTION DRUG LABEL	1	65483-093	CAPSULE	3 mg	ORAL	NDA	23 sections
Auranofin	HUMAN PRESCRIPTION DRUG LABEL	1	85437-093	CAPSULE	3 mg	ORAL	NDA authorized generic	23 sections

Product

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

auranofin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: